Imvax secures $29m to support Phase IIb glioblastoma therapy trial
Imvax has secured $29m in a financing round from current investors, aimed at advancing the Phase IIb trial of its autologous ...
Personalized therapy for rare genetic diseases: Patient-derived organoids offer new hope
Children's Mercy Kansas City has achieved a significant advancement toward the treatment of rare genetic diseases through the ...
biopharma-reporter7d
Amylyx Pharmaceuticals gets FDA go ahead for phase 1 ALS trial
The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...
Healio7d
FDA grants fast-track designation to myotonic dystrophy type 1 treatment
The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat individuals with myotonic ...
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen (STK-001), its investigational candidate for treating Dravet syndrome, a severe and progressive ...
chromatographyonline27d
Advancing Gene Therapy: Enzyme Selection for Effective RNA Oligonucleotide Mapping
New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), continue to make progress in both primate and first-in-human trials. As this ...
chromatographyonline27d
Hydrophilic Interaction Chromatography for the Analysis of Therapeutic Oligonucleotides: An Interview with Davy Guillarme
Guillarme recently spoke with LCGC International about his work analyzing therapeutic oligonucleotides. What are oligonucleotides? How do they differ from nucleotides? What is their benefit?
8 recent scientific breakthroughs
New scientific research is coming out every day, but a lot of it does not make major headlines. Some of these findings, however, have the potential to change the world. Here are eight recent ...